NLG919 is a promising and potent direct enzymatic inhibitor of IDO,In preclinical models, NLG919 showed dose dependent activation and proliferation of effector T cells, producing dramatic regression of large established tumors. Additionally, NLG919 showed enhanced immune activation and tumor regression when combined with Indoximod in this system.
Reference:
1.J Immunother Cancer. 2014; 2(Suppl 3): P250. Published online 2014 Nov 6. doi: 10.1186/2051-1426-2-S3-P250
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292544/
仅供研究使用。 我们不向患者出售。
名称 | NLG919(GDC0919) |
---|---|
Iupac 化学名称 | 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
同义词 | NLG 919;NLG-919;GDC0919;RG6078. |
英文同义词 | NLG 919;NLG-919;GDC0919;RG6078. |
分子式 | C18H22N2O |
分子量 | 282.38 |
Smile | OC(C1CCCCC1)CC(C2=C3C=CC=C2)N4C3=CN=C4 |
InChiKey | YTRRAUACYORZLX-UHFFFAOYSA-N |
InChi | InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2 |
Cas号 | 1402836-58-1 |
相关CAS号 |
包装 | 价格 | 库存 | 纯度 | 备货期 |
---|---|---|---|---|
大货 | 询价 | 询价 | 询价 |